676 related articles for article (PubMed ID: 17896900)
1. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.
Sheffield CA; Kane MP; Busch RS
Pharmacotherapy; 2007 Oct; 27(10):1449-55. PubMed ID: 17896900
[TBL] [Abstract][Full Text] [Related]
2. Stabilizing effect of exenatide in a patient with C-peptide-negative diabetes mellitus.
Paisley AN; Savage MW; Wiles PG
Diabet Med; 2009 Sep; 26(9):935-8. PubMed ID: 19719716
[TBL] [Abstract][Full Text] [Related]
3. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
Pinelli NR; Cha R; Brown MB; Jaber LA
Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
[TBL] [Abstract][Full Text] [Related]
4. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
[TBL] [Abstract][Full Text] [Related]
5. Beyond glycemic control: the effects of incretin hormones in type 2 diabetes.
Martin CL
Diabetes Educ; 2008; 34 Suppl 3():66S-72S. PubMed ID: 18525067
[TBL] [Abstract][Full Text] [Related]
6. Diffusion into use of exenatide for glucose control in diabetes mellitus: a retrospective cohort study of a new therapy.
Segal JB; Dy SM; Millman EA; Herbert R; Bass EB; Wu A
Clin Ther; 2007 Aug; 29(8):1784-94. PubMed ID: 17919559
[TBL] [Abstract][Full Text] [Related]
7. Exenatide: a novel incretin mimetic agent for treating type 2 diabetes mellitus.
Lam S; See S
Cardiol Rev; 2006; 14(4):205-11. PubMed ID: 16788334
[TBL] [Abstract][Full Text] [Related]
8. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
Kim D; MacConell L; Zhuang D; Kothare PA; Trautmann M; Fineman M; Taylor K
Diabetes Care; 2007 Jun; 30(6):1487-93. PubMed ID: 17353504
[TBL] [Abstract][Full Text] [Related]
9. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.
Gallwitz B
Int J Clin Pract; 2006 Dec; 60(12):1654-61. PubMed ID: 17109672
[TBL] [Abstract][Full Text] [Related]
10. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes.
Ghofaili KA; Fung M; Ao Z; Meloche M; Shapiro RJ; Warnock GL; Elahi D; Meneilly GS; Thompson DM
Transplantation; 2007 Jan; 83(1):24-8. PubMed ID: 17220786
[TBL] [Abstract][Full Text] [Related]
11. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.
Mari A; Nielsen LL; Nanayakkara N; DeFronzo RA; Ferrannini E; Halseth A
Horm Metab Res; 2006 Dec; 38(12):838-44. PubMed ID: 17163361
[TBL] [Abstract][Full Text] [Related]
12. Exenatide: a new option for the treatment of type 2 diabetes.
Yoo BK; Triller DM; Yoo DJ
Ann Pharmacother; 2006 Oct; 40(10):1777-84. PubMed ID: 16985091
[TBL] [Abstract][Full Text] [Related]
13. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
Linnebjerg H; Kothare PA; Skrivanek Z; de la Peña A; Atkins M; Ernest CS; Trautmann ME
Diabet Med; 2006 Mar; 23(3):240-5. PubMed ID: 16492205
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
Cervera A; Wajcberg E; Sriwijitkamol A; Fernandez M; Zuo P; Triplitt C; Musi N; DeFronzo RA; Cersosimo E
Am J Physiol Endocrinol Metab; 2008 May; 294(5):E846-52. PubMed ID: 18334612
[TBL] [Abstract][Full Text] [Related]
15. Incretin mimetics as a novel therapeutic option for hepatic steatosis.
Tushuizen ME; Bunck MC; Pouwels PJ; van Waesberghe JH; Diamant M; Heine RJ
Liver Int; 2006 Oct; 26(8):1015-7. PubMed ID: 16953843
[TBL] [Abstract][Full Text] [Related]
16. Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes.
Taylor K; Kim D; Nielsen LL; Aisporna M; Baron AD; Fineman MS
Horm Metab Res; 2005 Oct; 37(10):627-32. PubMed ID: 16278786
[TBL] [Abstract][Full Text] [Related]
17. Exenatide therapy in insulin-treated type 2 diabetes and obesity.
Nayak UA; Govindan J; Baskar V; Kalupahana D; Singh BM
QJM; 2010 Sep; 103(9):687-94. PubMed ID: 20624837
[TBL] [Abstract][Full Text] [Related]
18. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
19. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
[TBL] [Abstract][Full Text] [Related]
20. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
Halimi S
Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]